The Claim
In adults with cardiovascular disease, semaglutide is associated with a significantly higher rate of gastrointestinal adverse events leading to permanent treatment discontinuation, with 10.0% of treated individuals experiencing such side effects compared to 2.0% on placebo, representing an 8.4% absolute increase in risk and indicating that one in every 12 treated patients discontinues treatment due to gastrointestinal side effects.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with heart disease, taking semaglutide means about 1 in 12 will stop treatment because of stomach problems like nausea or diarrhea — much more common than with a dummy pill.
See the scientific wording
Semaglutide is associated with a significantly higher rate of gastrointestinal adverse events leading to permanent treatment discontinuation in adults with cardiovascular disease, with 10.0% experiencing such side effects compared to 2.0% on placebo, resulting in an 8.4% absolute increase in risk and one in every 12 treated individuals stopping treatment due to side effects.
What the research says
1 studyStudy: Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
The study looked at the same medicine (semaglutide) in similar patients and found exactly what the claim says: 10% of people on the drug stopped because of stomach side effects, compared to 2% on placebo, meaning about 1 in 12 people had to quit.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.